Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYABRA, INC.CYAB · Entity 8037 | Director · Chief Product Officer | July 10, 2026 | July 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYABRA, INC.
Report date July 10, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 894,199 |
Reported balance
After 2026-07-10 transaction · row 1
1 source rowRow 1 · 2026-07-10 · Grant · Acquired 53,650 · Balance 894,199 F1: On July 10, 2026, the Reporting Person purchased 53,650 shares of common stock, par value $0.0001 per share (the "Common Stock"), from the Issuer in a private placement transaction (the "Private Placement") at a purchase price of $0.435 per share. |
| Common Stock Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.45 | Direct | 53,650 |
Reported balance
After 2026-07-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-10 · Purchase · Acquired 53,650 · Balance 53,650 F2: The Reporting Person purchased Series B warrants to purchase up to 53,650 shares of Common Stock (the "Series B Warrants") in the Private Placement. F3: The Series B Warrants will become exercisable upon the receipt of the requisite stockholder approval. F4: The Series B Warrants expire twelve (12) months following the initial exercise date. |
| Common Stock Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 | Direct | 107,300 |
Reported balance
After 2026-07-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-10 · Purchase · Acquired 53,650 · Balance 107,300 F5: The Reporting Person purchased Series A warrants to purchase up to 53,650 shares of Common Stock (the "Series A Warrants") in the Private Placement. F6: The Series A Warrants will become exercisable upon the receipt of the requisite stockholder approval. F7: The Series A Warrants expire five (5) years following the initial exercise date. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 10, 2026, the Reporting Person purchased 53,650 shares of common stock, par value $0.0001 per share (the "Common Stock"), from the Issuer in a private placement transaction (the "Private Placement") at a purchase price of $0.435 per share.
F2: The Reporting Person purchased Series B warrants to purchase up to 53,650 shares of Common Stock (the "Series B Warrants") in the Private Placement.
F3: The Series B Warrants will become exercisable upon the receipt of the requisite stockholder approval.
F4: The Series B Warrants expire twelve (12) months following the initial exercise date.
F5: The Reporting Person purchased Series A warrants to purchase up to 53,650 shares of Common Stock (the "Series A Warrants") in the Private Placement.
F6: The Series A Warrants will become exercisable upon the receipt of the requisite stockholder approval.
F7: The Series A Warrants expire five (5) years following the initial exercise date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2026 Filed Jul 13, 2026 21:10 UTC | CYABRA, INC. CYAB · Entity 8037 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 53,650 | $0.50 Strike: $0.50 | $26,825.00 |
DisclosureSEC source: 0001213900-26-077646 · ownership.xml · derivative · entry 3 Daar Yossef · CIK 0002045600 · Director · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,300 Underlying: Common Stock · 53,650 shares Expires not disclosed F5 · security: The Reporting Person purchased Series A warrants to purchase up to 53,650 shares of Common Stock (the "Series A Warrants") in the Private Placement. F6 · derivative.exercise_date: The Series A Warrants will become exercisable upon the receipt of the requisite stockholder approval. F7 · derivative.expiration_date: The Series A Warrants expire five (5) years following the initial exercise date. Read SEC document |
| July 10, 2026 Filed Jul 13, 2026 21:10 UTC | CYABRA, INC. CYAB · Entity 8037 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 53,650 | $0.45 Strike: $0.45 | $24,142.50 |
DisclosureSEC source: 0001213900-26-077646 · ownership.xml · derivative · entry 2 Daar Yossef · CIK 0002045600 · Director · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,650 Underlying: Common Stock · 53,650 shares Expires not disclosed F2 · security: The Reporting Person purchased Series B warrants to purchase up to 53,650 shares of Common Stock (the "Series B Warrants") in the Private Placement. F3 · derivative.exercise_date: The Series B Warrants will become exercisable upon the receipt of the requisite stockholder approval. F4 · derivative.expiration_date: The Series B Warrants expire twelve (12) months following the initial exercise date. Read SEC document |
| July 10, 2026 Filed Jul 13, 2026 21:10 UTC | CYABRA, INC. CYAB · Entity 8037 | GrantCommon Stock | 53,650 | $0.44 | $23,337.75 |
DisclosureSEC source: 0001213900-26-077646 · ownership.xml · nonDerivative · entry 1 Daar Yossef · CIK 0002045600 · Director · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 894,199 F1 · shares: On July 10, 2026, the Reporting Person purchased 53,650 shares of common stock, par value $0.0001 per share (the "Common Stock"), from the Issuer in a private placement transaction (the "Private Placement") at a purchase price of $0.435 per share. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:01 UTC | CYABRA, INC. CYAB · Entity 8037 | GrantCommon Stock | 130,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-058421 · ownership.xml · nonDerivative · entry 1 Daar Yossef · CIK 0002045600 · Director · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 840,549 F1 · shares: On May 14, 2026, the Reporting Person was granted 130,000 restricted stock units ("RSUs") of the Issuer pursuant to the Cyabra, Inc. 2026 Omnibus Equity Incentive Plan, vesting in quarterly amounts of 26,000 shares of common stock, par value $0.0001 per share (the "Common Stock") through July 1, 2027. Each RSU represents the right to receive one Common Stock. Read SEC document |
| March 27, 2026 Filed Apr 1, 2026 01:10 UTC | CYABRA, INC. CYAB · Entity 8037 | GrantCommon Stock | 133,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-037861 · ownership.xml · nonDerivative · entry 2 Daar Yossef · CIK 0002045600 · Director · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 710,549 F4 · shares: On March 27, 2026, the Reporting Person was granted 133,000 restricted stock units of the Issuer pursuant to the Cyabra, Inc. 2026 Omnibus Equity Incentive Plan (the "2026 Plan") which were fully vested upon grant. Such grant is effective 30 days after the 2026 Israeli Sub-Plan to the 2026 Plan is filed with the Israel Tax Authority. F3 · ownership.nature: Held by IBI Trust Management in trust for the Reporting Person. Read SEC document |
| March 27, 2026 Filed Apr 1, 2026 01:10 UTC | CYABRA, INC. CYAB · Entity 8037 | GrantCommon Stock | 577,549 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-037861 · ownership.xml · nonDerivative · entry 1 Daar Yossef · CIK 0002045600 · Director · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 577,549 F1 · shares: Received in connection with the Issuer's business combination with Trailblazer Merger Corporation I ("Trailblazer"), in accordance with the terms of the Merger Agreement, dated July 22, 2024, as amended (the "Merger Agreement"), by and among Trailblazer, Trailblazer Merger Sub, Ltd. ("Merger Sub"), Trailblazer Holdings, Inc. ("Holdings"), and Cyabra Strategy Ltd. ("Cyabra"), pursuant to which (a) Trailblazer merged with and into Holdings, with Holdings as the surviving entity of the merger (the "Parent Merger"), and (b) Merger Sub merged with and into Cyabra, with Cyabra as the surviving entity of the merger (together with the Parent Merger and all other transactions contemplated by the Merger Agreement, the "Business Combination"), following which Merger Sub ceased to exist and Cyabra became a wholly owned subsidiary of Holdings. After giving effect to the Business Combination, Holdings changed its name to the Issuer. F2 · shares: Pursuant to the Merger Agreement, 160,000 ordinary shares of Cyabra held by the Reporting Person that were outstanding immediately prior to the effective time of the Business Combination (the "Effective Time") were, as of the Effective Time, converted into 577,549 shares of the Issuer. F1 · price: Received in connection with the Issuer's business combination with Trailblazer Merger Corporation I ("Trailblazer"), in accordance with the terms of the Merger Agreement, dated July 22, 2024, as amended (the "Merger Agreement"), by and among Trailblazer, Trailblazer Merger Sub, Ltd. ("Merger Sub"), Trailblazer Holdings, Inc. ("Holdings"), and Cyabra Strategy Ltd. ("Cyabra"), pursuant to which (a) Trailblazer merged with and into Holdings, with Holdings as the surviving entity of the merger (the "Parent Merger"), and (b) Merger Sub merged with and into Cyabra, with Cyabra as the surviving entity of the merger (together with the Parent Merger and all other transactions contemplated by the Merger Agreement, the "Business Combination"), following which Merger Sub ceased to exist and Cyabra became a wholly owned subsidiary of Holdings. After giving effect to the Business Combination, Holdings changed its name to the Issuer. F2 · price: Pursuant to the Merger Agreement, 160,000 ordinary shares of Cyabra held by the Reporting Person that were outstanding immediately prior to the effective time of the Business Combination (the "Effective Time") were, as of the Effective Time, converted into 577,549 shares of the Issuer. F1 · balance_after: Received in connection with the Issuer's business combination with Trailblazer Merger Corporation I ("Trailblazer"), in accordance with the terms of the Merger Agreement, dated July 22, 2024, as amended (the "Merger Agreement"), by and among Trailblazer, Trailblazer Merger Sub, Ltd. ("Merger Sub"), Trailblazer Holdings, Inc. ("Holdings"), and Cyabra Strategy Ltd. ("Cyabra"), pursuant to which (a) Trailblazer merged with and into Holdings, with Holdings as the surviving entity of the merger (the "Parent Merger"), and (b) Merger Sub merged with and into Cyabra, with Cyabra as the surviving entity of the merger (together with the Parent Merger and all other transactions contemplated by the Merger Agreement, the "Business Combination"), following which Merger Sub ceased to exist and Cyabra became a wholly owned subsidiary of Holdings. After giving effect to the Business Combination, Holdings changed its name to the Issuer. F2 · balance_after: Pursuant to the Merger Agreement, 160,000 ordinary shares of Cyabra held by the Reporting Person that were outstanding immediately prior to the effective time of the Business Combination (the "Effective Time") were, as of the Effective Time, converted into 577,549 shares of the Issuer. F3 · ownership.nature: Held by IBI Trust Management in trust for the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.